+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

  • PDF Icon

    Report

  • 211 Pages
  • March 2025
  • Region: Global
  • BCC Research
  • ID: 4721295
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.

The global cancer therapeutics market emphasis on recurrent and metastatic divisions was valued at $108.1 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.7% to reach $168 billion by the end of 2029. There are several reasons why the oncology pharmaceutical sector is a promising one for growth. The dynamic and quickly changing oncology pharmaceutical market is a part of the global pharmaceutical industry. The development, manufacturing and distribution of medications used to treat cancer are the main objectives of this market, which is anticipated to keep expanding considering the continuous developments in science and technology. Novel immunotherapies and CAR-T cell therapy are two emerging treatments that could completely change the way cancer is treated. The accessibility and affordability of medications must be addressed to ensure that new treatments benefit a wide range of patients.

The movement of cancer cells from their original locations to different areas of the body is known as “metastasis” or “metastatic cancer.” Cancer cells separate from the original tumor during metastasis, move through the blood or lymphatic system and develop into a new tumor in different body tissues or organs. The primary tumor and the new metastatic tumor are the same type of cancer. Breast cancer cells, not lung cancer cells, are present in the lung if the disease spreads there.

Compared to localized cancers, metastatic cancer usually has a worse prognosis, and it is more challenging to treat. Given the aggressive nature of metastatic disease and the difficulty of overcoming resistance to current therapies, there is a significant need for novel treatments for metastatic cancers, making this market crucial. There are more metastatic cases due to patients living longer after initial treatment due to advances in cancer detection and treatment. Approximately 90% of cancer-related deaths are thought to be caused by metastases (Chaffer CL et al., Science, 2011). With the advent of combination therapies, which combine immunotherapy, targeted therapy and chemotherapy to boost efficacy and overcome resistance, the market for treatments for metastatic cancer is rapidly changing.

Genetic profiling and biomarker testing enable treatments specific to each patient’s cancer type and mutations, so personalized medicine is increasingly playing a crucial role in the treatment of metastatic cancers.

Report Scope

Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.

Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions - North America, Europe, Asia-Pacific and the Rest of the World - as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.

Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope.

Cancer types noted in this report include:

  • Lung.
  • Breast.
  • Liver.
  • Stomach.
  • Prostate.
  • Colorectal.
  • Gastric.
  • Cervical.
  • Bladder.
  • Kidney.
  • Ovarian.
  • Lymphoma.
  • Multiple myeloma.
  • Brain tumors.
  • Thyroid.
  • Uterine.
Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.

For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.

Report Includes

  • 51 data tables and 83 additional tables
  • An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
  • Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
  • A look at the factors driving the market’s growth and constraints
  • Insight into the industry value chain analysis, providing a study of the intermediaries involved
  • Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
  • Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
  • Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
  • Identification of the fastest-growing applications and technologies, and a review of current market trends
  • Discussion of the industry’s ESG challenges and practices
  • Review of the current market status, technology issues, industry value chain, Porter’s Five Forces, competitive landscape, R&D activity and patent analysis
  • Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
  • Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
  • Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Overview
  • Metastatic or Recurrent Cancer Treatment Types
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Targeted Therapy
  • Cancer Immunotherapies
  • Oncolytic Virotherapy
  • Antibody-Drug Conjugates
  • Porter's Five Forces Analysis in the Oncology Market
  • Potential of New Entrants
  • Bargaining Power of Suppliers
  • Bargaining Power of Buyers
  • Threat of Substitute Products or Services
  • Industry Rivalry: High
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Robust Approval of Oncology Drugs
  • Technological Advances in Cancer Treatments
  • Increasing Incidence of Cancer Disease
  • Market Restraints
  • Loss of Exclusivity and Genericization
  • Lack of Oncology Professionals
  • Market Opportunities
  • Incorporation of Artificial Intelligence in Oncology
  • Promising Drugs in the Late Stage of the Pipeline
Chapter 4 Regulatory Landscape
  • The U.S. Approval Process
  • FDA Regulatory Considerations for Oncology Drug Development
  • European Union Approval Process
  • Current Situation in E.U. Approval Process
  • Japanese Approval Process
Chapter 5 Emerging Trends and Pipeline Analysis
  • Emerging Technologies
  • Personalized Cancer Vaccines
  • Test to Identify 18 Early-Stage Cancers
  • CAR T-Cell Therapy
  • Artificial Intelligence
Tablet to Cut Breast Cancer Risk
  • Nanoparticles
  • Pressurized Intraperitoneal Aerosol Chemotherapy
  • Cervical Cancer Treatment Breakthrough
  • New Developments
  • Biosimilar Approvals
  • Pipeline Analysis
  • Clinical Trial Analysis
  • Patent Analysis
  • Key Takeaways
Chapter 6 Supply Chain Analysis
  • Overview
  • Research and Development
  • Manufacturing
  • Packaging
  • Wholesale Distributors and Repackagers
  • Pharmacies
  • Dispensed to Consumers
  • Cancer Drug Shortage
  • Costs
  • Manufacturing Complexity
  • Geographic Concentration
  • Quality
Chapter 7 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Analysis, by Cancer Type
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Liver Cancer
  • Cervix Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • All Other Cancers
  • Geographic Breakdown
  • Market Analysis, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8 Competitive Intelligence
  • Overview
  • Blockbuster Oncology Pharmaceutical Brands
  • Global Market Shares of Leading Companies
Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective
  • Role of ESG in the Pharma Industry
  • ESG Performance Analysis
  • Environmental Factors
  • Social Issues
  • Governance Factors
  • ESG Risk Ratings
  • Conclusion
Chapter 10 Appendix
  • Methodology
  • Emerging Start-ups/Market Disruptors
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • JOHNSON & JOHNSON SERVICES INC.
  • LILLY
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.
List of Tables
Summary Table: Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 1: Typical Various Metastatic Cancer Treatments
Table 2: Promising Drugs in Late Stage of Pipeline, 2023
Table 3: FDA Drug Approvals in Oncology, 2021-2023
Table 4: Oncology Drug Approvals, 2020-July 2024
Table 5: Novel Oncology Drug Approvals for Relapsed or Metastatic Cancers, 2021-November 2024*
Table 6: FDA Approved Biosimilar for Oncology Indications, 2015-2024
Table 7: FDA Approved Biosimilars and Interchangeable Biosimilars, by FDA, July 2024
Table 8: EMA Approved Biosimilar for Oncology Indications, 2007-July 2024
Table 9: Clinical Trial Drugs for Metastatic Cancers in Phases 3 and 4, 2024
Table 10: Granted Patents in Metastatic Cancer Field, 2022-2024
Table 11: Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 12: Clinical Trial Study for Metastatic Lung Cancer, 2024
Table 13: Global Market for Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 14: Common Drugs Used to Treat Metastatic Breast Cancer, 2023
Table 15: Clinical Trial Studies for Metastatic Breast Cancer, 2024
Table 16: Global Market for Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 17: Clinical Trial Study for Metastatic Colorectal Cancer, 2024
Table 18: Global Market for Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 19: Clinical Trial Study for Metastatic Prostate Cancer, 2024
Table 20: Global Market for Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 21: Clinical Trial Study for Metastatic Stomach Cancer, 2024
Table 22: Global Market for Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 23: Clinical Trial Study for Metastatic Liver Cancer, 2024
Table 24: Global Market for Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 25: Clinical Trial Study for Metastatic Cervical Cancer, 2024
Table 26: Global Market for Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 27: Clinical Trial Study for Metastatic Bladder Cancer, 2024
Table 28: Global Market for Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 29: Clinical Trial Study for Metastatic Kidney Cancer, 2024
Table 30: Global Market for Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 31: Clinical Trial Study for Metastatic Pancreatic Cancer, 2024
Table 32: Global Market for Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 33: Clinical Trial Study for Metastatic Ovarian Cancer, 2024
Table 34: Global Market for Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 35: Global Market for All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 36: Global Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 37: North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 38: North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 39: Incidence and Mortality of Cancer Cases in the U.S., Both Sexes, 2024
Table 40: U.S. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 41: Canadian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 42: Incidence and Mortality of Cancer Cases in Mexico, Both Sexes, 2022
Table 43: Mexican Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 44: European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 45: European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 46: Incidence and Mortality of Cancer Cases in Germany, Both Sexes, 2022
Table 47: German Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 48: U.K. New Diagnosed Cancer Cases, 2021 and 2022
Table 49: U.K. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 50: Cancer Incidence and Mortality Cases in Franch, Both Sexes, 2022
Table 51: French Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 52: Cancer Incidence and Mortality Cases in Spain, Both Sexes, 2022
Table 53: Spanish Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 54: Cancer Incidence and Mortality Cases in Italy, Both Sexes, 2022
Table 55: Italian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 56: Rest of the European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 57: Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 58: Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 59: Cancer Incidence and Mortality in China, Both Sexes, 2022
Table 60: Chinese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 61: Japanese Cancer Incidence and Mortality, Both Sexes, 2022
Table 62: Japanese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 63: Cancer Incidence and Mortality Cases in India, Both Sexes, 2022
Table 64: Indian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 65: Cancer Incidence and Mortality Cases in South Korea, Both Sexes, 2022
Table 66: South Korean Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 67: Rest of Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 68: Rest of World Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 69: Drug Pipeline for Major Companies for Metastatic or Relapsed Condition, 2023
Table 70: ESG Risk Rankings for Oncology Pharmaceuticals Companies, Through January 2025
Table 71: List of a Few Emerging Startups
Table 72: Report Information Sources
Table 73: Abbreviations Used in the Global Cancer Therapeutics Market with Emphasis on Recurrent and Metastatic Divisions
Table 74: AbbVie Inc.: Company Snapshot
Table 75: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 76: AbbVie Inc.: Product Portfolio
Table 77: AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 78: Amgen Inc.: Company Snapshot
Table 79: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 80: Amgen Inc.: Product Portfolio
Table 81: Amgen Inc.: News/Key Developments, 2022-2024
Table 82: AstraZeneca: Company Snapshot
Table 83: AstraZeneca: Financial Performance, FY 2022 and 2023
Table 84: AstraZeneca: Product Portfolio
Table 85: AstraZeneca: News/Recent Developments, 2022-2024
Table 86: Bayer AG: Company Snapshot
Table 87: Bayer AG: Financial Performance, FY 2022 and 2023
Table 88: Bayer AG: Product Portfolio
Table 89: Bayer AG: News/Key Developments, 2023-2024
Table 90: Bristol-Myers Squibb Co.: Company Snapshot
Table 91: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 92: Bristol-Myers Squibb Co.: Product Portfolio
Table 93: Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 94: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98: Gilead Sciences Inc.: Company Snapshot
Table 99: Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 100: Gilead Sciences Inc.: Product Portfolio
Table 101: Gilead Sciences Inc.: News/Key Developments, 2022-2024
Table 102: Johnson & Johnson Services Inc.: Company Snapshot
Table 103: Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 104: Johnson & Johnson Services Inc.: Product Portfolio
Table 105: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 106: Lilly: Company Snapshot
Table 107: Lilly: Financial Performance, FY 2022 and 2023
Table 108: Lilly: Product Portfolio
Table 109: Lilly: News/Key Developments, 2023 and 2024
Table 110: Merck & Co. Inc.: Company Snapshot
Table 111: Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 112: Merck & Co. Inc.: Product Portfolio
Table 113: Merck & Co. Inc.: News/Key Developments, 2021-2024
Table 114: Novartis AG: Company Snapshot
Table 115: Novartis AG: Financial Performance, FY 2022 and 2023
Table 116: Novartis AG: Product Portfolio
Table 117: Novartis AG: News/Key Developments, 2022-2024
Table 118: Pfizer Inc.: Company Snapshot
Table 119: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 120: Pfizer Inc.: Product Portfolio
Table 121: Pfizer Inc.: News/Key Developments, 2021-2024
Table 122: Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 123: Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 124: Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 125: Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 126: Sanofi: Company Snapshot
Table 127: Sanofi: Financial Performance, FY 2022 and 2023
Table 128: Sanofi: Product Portfolio
Table 129: Sanofi: News/Key Developments, 2022-2024
Table 130: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 131: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 132: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 133: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021-2024
List of Figures
Summary Figure: Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 1: Porter’s Five Forces Analysis of the Oncology Market
Figure 2: Market Dynamics of the Global Cancer Therapeutics Market Emphasis on Recurrent and Metastatic Divisions
Figure 3: Novel Oncology Drugs with FDA Approvals, 2016-2024
Figure 4: U.S. Cancer Incidence, 2000-2021
Figure 5: Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
Figure 6: Oncology Drug Clinical Trial Studies, by Trial Phase, 2021-July 2024
Figure 7: Phase 3 and 4 Clinical Trial Studies of Oncology Drugs for Metastatic and Recurrent Division, by Company, July 2024
Figure 8: Top Applicants in Metastatic Cancer Patents, 2022-2024
Figure 9: Supply Chain Process of Pharmaceutical Drugs
Figure 10: Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 11: Global Market Share of Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 12: Global Market Share of Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 13: Global Market Share of Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 14: Global Market Share of Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 15: Global Market Share of Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 16: Global Market Share of Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 17: Global Market Share of Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 18: Global Market Share of Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 19: Global Market Share of Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 20: Global Market Share of Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 21: Global Market Share of Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 22: Global Market Share of All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 23: Global Market Share of Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 24: North American Market Share of Cancers Therapeutics Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 25: Share of Cancer Incidence Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 26: Share of Cancer Mortality Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 27: European Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 28: U.K. Current and Forecast Cancer Prevalence, 2020-2040
Figure 29: Asia-Pacific and Oceania Share of Cancer Incidence, Both Sexes, 2022
Figure 30: Asia-Pacific and Oceania Share of Cancer Mortality, Both Sexes, 2022
Figure 31: Asia-Pacific Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 32: Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
Figure 33: Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
Figure 34: AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35: AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36: Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37: Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 38: AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 39: AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 40: Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 41: Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 42: Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 43: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 44: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 45: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 46: Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 47: Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 48: Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 49: Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 50: Lilly: Revenue Share, by Business Unit, FY 2023
Figure 51: Lilly: Revenue Share, by Country/Region, FY 2023
Figure 52: Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 53: Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 54: Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 55: Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 56: Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 57: Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 58: Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 59: Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 60: Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 61: Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 62: Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 63: Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023

Samples

Loading
LOADING...

Companies Mentioned

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • JOHNSON & JOHNSON SERVICES INC.
  • LILLY
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.

Table Information